Mobocertinib(TAK-788):靶向EGFR外显子20插入突变NSCLC的抑制剂
本文报道一种新型不可逆EGFR酪氨酸激酶抑制剂mobocertinib(TAK-788),专门设计用于强效抑制携带EGFR外显子20插入(EGFRex20ins)突变的致癌变异,并选择性优于野生型EGFR。在工程化及患者来源的多种EGFRex20ins突变模型中评估体外和体内活性,mobocertinib抑制多种EGFRex20ins驱动细胞系活力的效力优于已批准EGFR TKI,并在患者来源异种移植和小鼠原位模型中显示体内抗肿瘤疗效。这些发现支持mobocertinib治疗EGFRex20ins突变NSCLC的临床开发。
要点
- Mobocertinib专门设计强效抑制EGFRex20ins突变并对野生型EGFR具选择性。
- 体外抑制EGFRex20ins驱动细胞系活力优于已批准EGFR TKI。
- 患者来源异种移植和小鼠原位模型显示体内抗肿瘤疗效。
核心结论
- Mobocertinib在临床前模型中显示对EGFRex20ins突变NSCLC的抑制活性,支持其临床开发。
研究设计与样本
- 临床前研究,在工程化及患者来源的多种EGFRex20ins突变模型中评估mobocertinib的体外和体内活性。
主要发现
- Mobocertinib抑制多种EGFRex20ins驱动细胞系活力的效力优于已批准EGFR TKI。
- Mobocertinib在患者来源异种移植和小鼠原位模型中显示体内抗肿瘤疗效。
临床怎么用
- 临床前数据支持在EGFR外显子20插入突变NSCLC患者中开展mobocertinib的临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most EGFR exon 20 insertion (EGFRex20ins) driver mutations in non-small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKI). To address the limitations of existing therapies targeting EGFR-mutated NSCLC, mobocertinib (TAK-788), a novel irreversible EGFR TKI, was specifically designed to potently inhibit oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. The in vitro and in vivo activity of mobocertinib was evaluated in engineered and patient-derived models harboring diverse EGFRex20ins mutations. Mobocertinib inhibited viability of various EGFRex20ins-driven cell lines more potently than approved EGFR TKIs and demonstrated in vivo antitumor efficacy in patient-derived xenografts and murine orthotopic models. These findings support the ongoing clinical development of mobocertinib for the treatment of EGFRex20ins-mutated NSCLC. SIGNIFICANCE: No oral EGFR-targeted therapies are approved for EGFR exon 20 insertion (EGFRex20ins) mutation-driven NSCLC. Mobocertinib is a novel small-molecule EGFR inhibitor specifically designed to target EGFRex20ins mutants. Preclinical data reported here support the clinical development of mobocertinib in patients with NSCLC with EGFR exon 20 insertion mutations.See related commentary by Pacheco, p. 1617.This article is highlighted in the In This Issue feature, p. 1601.
引用
- Gonzalvez F, Vincent S, Baker TE, et al. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021. PMID: 33632773. doi:10.1158/2159-8290.CD-20-1683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。